Revenues beat expectations, EPS in line with expectations

Merck KGaA (ETR:MRK) Q2 2024 results

Key Financial Results

• Revenues: EUR 5.35 billion (unchanged compared to Q2 2023).

• Net income: EUR 607.0 million (down 14% compared to Q2 2023).

• Profit margin: 11% (down from 13% in Q2 2023).

• Earnings per share: EUR 1.40 (down from EUR 1.62 in Q2 2023).

All numbers shown in the chart above are for the last 12 months (TTM)

Merck KGaA revenues exceeded expectations

Revenue beat analyst estimates by 2.0%. Earnings per share (EPS) were mostly in line with analyst estimates.

Revenues are forecast to grow by an average of 4.5% per year over the next three years, while the pharmaceutical industry in Germany is forecast to grow by 3.7%.

Efficiency German pharmaceutical industry.

The company’s shares were up 2.5% from the previous week.

Balance sheet analysis

While it is very important to consider the income statement, you can also learn a lot about a company by looking at its balance sheet. We have done some analysis and you can read our opinion on the balance sheet of Merck KGaA.

Have an opinion on this article? Concerned about the content? contact us with us directly. You can also email us at editorial-team (at) simplywallst.com.

This Simply Wall St article is for general information purposes only. Our commentary is based solely on historical data and analyst forecasts, and is based on an objective methodology. Our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or your financial situation. Our goal is to provide you with long-term, focused analysis based on fundamental data. Please note that our analysis may not reflect the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Contact us directly. Alternatively, send an email to [email protected]